The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10907 malaria professionals are enjoying the free benefits of MalariaWorld today

plasmodial inhibitors

NOT Open Access | Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors

May 5, 2021 - 10:59 -- NOT Open Access
Author(s): 
Kayamba F, Malimabe T, Karpoormath R, et al.
Reference: 
Eur J Med Chem. 2021 May 5;217:113330

Presently, artemisinin-based combination therapy (ACT) is the first-line therapy of Plasmodium falciparum malaria. With the emergence of malaria parasites that are resistant to ACT, alternative antimalarial therapies are urgently needed. In line with this, we designed and synthesised a series of novel N-(7-chloroquinolin-4-yl)-N'-(4,6-diphenylpyrimidin-2-yl)alkanediamine hybrids (6a-7c) and evaluated their inhibitory activity against the NF54 chloroquine-susceptible strain as a promising class of antimalarial compounds.

Subscribe to RSS - plasmodial inhibitors